Background The risk and prognosis of VTE associated with oncologic surgery need to be
quantified to guide patient management. We aimed to examine the availability of data and to …

Ovarian cancer is the most lethal gynecological malignancy, which is due to late
presentation. Treating advanced stage ovarian cancer is difficult, and tumor recurrence and …

Importance Current guidelines recommend a 28-day course of enoxaparin for
thromboprophylaxis after surgery for gynecologic cancer. The high cost of this medication …

Background Podoplanin (PDPN) is a sialylated membrane glycoprotein that binds to C‐type
lectin‐like receptor 2 on platelets resulting in platelet activation. PDPN is expressed on …

Computation-based drug-repurposing/repositioning approaches can greatly speed up the
traditional drug discovery process. To date, systematic and comprehensive computation …

Ovarian cancer (OC) is one of the deadliest gynecological cancers, largely due to the fast
development of metastasis and drug resistance. The immune system is a critical component …

Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial
ovarian carcinoma. Late‐stage CCOC is not responsive to gold‐standard chemotherapy and …

OBJECTIVE: To identify the incidence and timing of venous thromboembolism as well as
any associated risk factors in patients with ovarian, fallopian tube, or primary peritoneal …

Simple Summary Ovarian clear cell carcinoma (OCCC) has a poor prognosis in advanced
cases and displays resistance to standard treatments for epithelial ovarian cancer. OCCC …

Simple Summary The exploration of prognostic biomarkers in ovarian cancer (OC) persists
due to the daunting challenge of therapy resistance and poor patient outcomes …